Renaissance Technologies LLC Purchases 129,900 Shares of OnKure Therapeutics, Inc. $OKUR

Renaissance Technologies LLC grew its position in OnKure Therapeutics, Inc. (NASDAQ:OKUR) by 52.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 377,250 shares of the company’s stock after buying an additional 129,900 shares during the quarter. Renaissance Technologies LLC’s holdings in OnKure Therapeutics were worth $1,562,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in OKUR. ADAR1 Capital Management LLC bought a new position in OnKure Therapeutics in the fourth quarter valued at approximately $2,941,000. Shay Capital LLC raised its holdings in shares of OnKure Therapeutics by 17.4% during the 3rd quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock worth $2,524,000 after buying an additional 135,888 shares in the last quarter. Prosight Management LP raised its holdings in shares of OnKure Therapeutics by 204.9% during the 4th quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after buying an additional 548,950 shares in the last quarter. Rosalind Advisors Inc. bought a new stake in shares of OnKure Therapeutics during the 4th quarter worth $2,118,000. Finally, Kotler Kevin acquired a new stake in OnKure Therapeutics in the fourth quarter valued at about $573,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Price Performance

Shares of OnKure Therapeutics stock opened at $3.93 on Thursday. OnKure Therapeutics, Inc. has a one year low of $2.18 and a one year high of $5.38. The business has a 50-day simple moving average of $4.25 and a 200 day simple moving average of $3.86. The firm has a market capitalization of $158.77 million, a price-to-earnings ratio of -1.12 and a beta of 0.29.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.23. On average, sell-side analysts expect that OnKure Therapeutics, Inc. will post -2.57 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on OKUR. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. JonesTrading downgraded shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Weiss Ratings cut OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Finally, HC Wainwright decreased their price target on shares of OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research report on Monday, July 20th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $21.00.

OnKure Therapeutics Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.